ABUSArbutus Biopharma Corporation

Healthcare

$4.20-5.2% 1Y

$4.20

$3.6752 weeks$5.20

Price

-5.2%1Y

End-of-day closes, not the intraday tick.

A mixed picture: the questions disagree

Quality shaky, nothing alarming, growth steady, the market undecided.

RyuScore 46 of 100: see how it is built

P/E5.3

Market value$831.0M

1 year-5.2%

5 years+2.9%

Charts

As reported to the SEC, without any scoring.

Arbutus Biopharma Corporation (ABUS) reported revenue of $1.0M in Q2 2026 (quarter ended Jun 30, 2026), down 91% from the same quarter a year earlier. That came with net loss of $5.1M. For the full year FY2025, revenue was $14M (+128% year on year) and net income −$34M. Its largest product in Q2 2026 was License at $632K, 62% of the disclosed total, well ahead of Collaboration And Contracts at 20%. The next results filing is expected around Nov 12, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

Oct 22, 2026On October 22, 2026, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has lifted the clinical hold on the Investigational New Drug application for AB-101, the Company’s oral PD-L1 inhibitor.Other event · Form 8-K
Aug 21, 2026On August 21, 2026, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its plans to launch a modified “Dutch auction” tender offer to purchase up to US$230 million in value of its common shares, at a price ranging from US$5.00 to US$5.75.Other event · Form 8-K
Aug 12, 2026Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release